When used in combination with PD-1 antagonists, CCX872 has been found to reduces myeloid-derived suppressive cells (MDSC) in tumor, enhance the activation of IFN axis and T cells, reduce exhaustion of T cells and improve tumor-killing ability, thereby benefiting the survival of mice bearing Kr15829. This evidence concerns the gene IFNA1 and neoplasm.